Loading ....
Lentivirus Production Services
Enhancing Gene Therapy with Precision Lentivirus Packaging
Lentiviral Vectors (LVs): Revolutionizing Gene Therapy Across Cell TypesLentiviral vectors (LVs), distinct from other retroviral vectors, belong to the Retroviridae family of RNA viruses. Their unique capability to infect both dividing and non-dividing cells marks them as a versatile tool in modern medical research. The body of research on lentiviral vectors is not only rapidly expanding but also encompasses a wide array of applications, highlighting their significance in the field of gene therapy.
One of the most notable features of LVs is their ability to integrate the foreign gene into the host’s chromosomal DNA. This integration ensures persistent and long-term expression of the therapeutic gene, a crucial aspect for sustained treatment effects. As a result, lentiviral vectors have become a cornerstone in developing treatments for a myriad of diseases.
LVs demonstrate remarkable infectivity across a diverse range of cell types, including but not limited to neurons, hepatocytes, cardiomyocytes, tumor cells, endothelial cells, and stem cells. This broad cellular tropism allows for targeted gene delivery to specific tissues, opening up new avenues in treating various genetic and acquired diseases. Their effectiveness in gene therapy has been substantiated by successful clinical trials conducted in the United States, showcasing promising outcomes that underscore their potential in clinical applications.
The versatility and efficacy of LVs position them as highly promising in the realm of gene therapy. With ongoing advancements and successful clinical applications, lentiviral vectors are poised to play a pivotal role in the future of medical treatments, offering hope for effective management and potential cures for a range of diseases. Their broad application prospects continue to inspire research and development, paving the way for groundbreaking therapeutic strategies.
Applications
1) Transfer the target gene/RNAi gene into cells that are difficult to transfect, such as neuronal cells, stem cells, or other primary cells;
2) Transfer the target gene or RNAi gene into animal tissues for long-term expression;
3) Construct a cell line stably expressing the target protein /RNAi
4) Gene therapy;
5) Transgenic animals;
6) Gene knockout;
7) Drug research: construct cell lines expressing receptor proteins to study the effects of drugs;
8) Rapid establishment of cell lines producing target proteins, a very promising eukaryotic expression method.
Lentivirus Advantages
-
Broad Cellular Tropism
Lentiviral vectors can infect a wide array of cell types, including both dividing and non-dividing cells. This makes them uniquely suitable for targeting various cell types such as neurons, hepatocytes, cardiomyocytes, tumor cells, endothelial cells, and stem cells. This broad cellular tropism enhances the applicability of your service in diverse research fields, including neuroscience, cardiology, oncology, and regenerative medicine.
-
Long-term Gene Expression:
Lentiviral vectors are integrated into the host cell's genome, ensuring long-term and stable expression of the therapeutic gene.This feature is critical for chronic disease models and gene therapy applications where sustained gene expression is necessary.
-
High Infection Efficiency:
These vectors are known for their high infection efficiency, which is essential for achieving effective gene delivery in various experimental and therapeutic settings. High infection efficiency leads to more consistent results in experiments and potential for lower doses in therapeutic applications.
-
Safety Profile:
Lentiviral vectors have been modified to enhance their safety, reducing the risk of inducing mutagenesis and other adverse effects. A strong safety profile is crucial for both laboratory research and clinical applications, particularly in gene therapy trials.
-
Customizability:
Our service offers customizability in vector design, including promoter choice, gene of interest, and reporter genes.
Customization allows researchers and clinicians to tailor the vectors to their specific needs, enhancing the relevance and efficacy of the vector in various applications.
-
Scalable Production:
We provide scalable production options, from small-scale for preliminary experiments to large-scale for clinical trials.
This scalability is essential for supporting projects at different stages, from basic research to clinical applications.
-
Compliance with Regulatory Standards:
Adherence to rigorous quality control and regulatory standards, ensuring that the products are suitable for use in advanced research and clinical trials. Compliance with regulatory standards is critical for ensuring the safety and efficacy of the vectors, particularly in the context of clinical trials and therapeutic applications.
-
Expert Support:
We offering expert technical support and consultation services to assist clients in vector design, application, and troubleshooting.
This support enhances the user experience and success rate, fostering long-term client relationships and advancing the field of gene therapy.
Pre-Made Control Vectors
Browse Available Control virus
Please see the chart below for our partial inventory of Pre-Made Control Vectors.| Control virus | Titer & Volume | Price |
|---|---|---|
| Lv--ZsGreen1 | ≥1.00×108TU/mL& 1mL | $210 |
| Lv-tdTomato | ≥1.00×108TU/mL& 1mL | $210 |
| Lv-NC-shRNA | ≥1.00×108TU/mL& 1mL | $210 |
| Lv--ZsGreen1 | ≥1.00×108TU/mL& 2 mL | $375 |
| Lv-tdTomato | ≥1.00×108TU/mL& 2 mL | $375 |
| Lv-NC-shRNA | ≥1.00×108TU/mL& 2 mL | $375 |
Lentivirus Production Services
Materials you must provide
| LVs services | Materials you must provide |
|---|---|
| Over-expression | gene information; the vector map; sequence |
| RNAi | RNAi sequence/ shRNA plasmid |
| Gene editing | gRNA sequence |
Price
| LV Services | Type | Titer & Volume | Turnaround | Prices* |
|---|---|---|---|---|
| Over-expression | GOI <2K | ≥1.00×108TU/mL& 1mL | 3-4 weeks | $735 |
| ≥1.00×108TU/mL& 2mL | 3-4 weeks | $1260 | ||
| GOI: 2K~3K | ≥1.00×108TU/mL& 1mL | 3-4 weeks | $840 | |
| ≥1.00×108TU/mL& 2mL | 3-4 weeks | $1620 | ||
| GOI > 3K | Enquiry | |||
| shRNA(knockdown) | shRNA (single) | ≥1.00×108TU/mL& 1mL | 3-4 weeks | $420 |
| ≥1.00×108TU/mL& 2mL | 3-4 weeks | $735 | ||
| shRNA（Three） | ≥1.00×108TU/mL& 1mL | 3-4 weeks | $1140 | |
| Lv-(Control ) | ≥1.00×108TU/mL& 1mL | 3-4 weeks | $315 | |
| ≥1.00×108TU/mL& 1mL | 3-4 weeks | $525 | ||
| Gene editing | Enquiry | |||
* additional fees are needed for plasmid construction services.
